-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, due to changes in the pharmaceutical environment, both multinational and local pharmaceutical companies are actively adapting to the changes and making corresponding business and personnel adjustments
.
Recently, AstraZeneca issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons
.
At the same time, Yu Qiran, the current director of new product planning and marketing, will also serve as the head of the project management office of the general manager of oncology
.
AstraZeneca's top management changes frequently.
According to incomplete statistics, 10 executives have left in the past 10 months, and there are many positions such as general manager and vice president
.
Among them, on March 15, 2022, Zhu Tong, vice president of AstraZeneca China and head of the Cardiovascular, Renal and Metabolism Division, announced his resignation, and his term will officially end on April 9, 2022
.
On 11, 2022, He Shuzhen, head of AstraZeneca's China and county markets, resigned
.
The reason for leaving is to seek external development opportunities
.
On December 11, 2021, Yin Min, General Manager of AstraZeneca China Oncology Division, resigned.
On the same day, AstraZeneca China Vice President and Head of Retail Division Wang Dong announced his resignation
.
On November 4, 2021, Du Haochen, vice president of AstraZeneca China and head of the county business department, resigned
.
It is worth mentioning that on October 15, 2021, He Yimin, assistant vice president of AstraZeneca China Digestive and Respiratory Nebulization Business Unit (GNR), announced his resignation
.
On September 22, 2021, AstraZeneca East RGM and Chairman of the Sales Advisory Committee Zhang Anwei resigned
.
On August 4, 2021, Xu Jing, Vice President of AstraZeneca China and Head of Digital and Business Innovation Department, announced his resignation due to seeking external career development opportunities
.
In July 2021, Dong Lijun, general manager of AstraZeneca's China Digestion and Whole Product Development Business Department, announced her resignation
.
From the perspective of the industry, behind the frequent resignation of senior executives of pharmaceutical companies, it is generally related to the company's performance, structural adjustment and other factors.
.
In terms of performance, AstraZeneca's 2021 financial report released on February 10 shows that its total revenue in China is $1.
312 billion, down from $1.
362 billion in 2020, which is also AstraZeneca's China's first drop in nearly five years
.
In the fourth quarter, revenue growth in China decreased by 4% year-on-year in 2020
.
As for the reasons for the decline in performance, AstraZeneca said that the main reason is "affected by price pressures related to medical insurance negotiations and centralized procurement policies
.
" In recent years, with the normalization of centralized procurement in China and the advancement of medical insurance, multinational pharmaceutical companies have also faced corresponding challenges.
Many multinational pharmaceutical companies have resigned, business adjustments, and even inevitably ushered in a "wave of layoffs"
.
For example, after the sixth batch of insulin centralized procurement, Novo Nordisk, which participated in the selection of all products, reported that it would lay off 15%-20% of its employees nationwide; Japanese pharmaceutical companies Daiichi Sankyo's Lesong tablets, Colabitux was not selected for the fourth batch of centralized procurement.
The company plans to combine cardiovascular, anti-infective and respiratory analgesia lines and lay off related teams
.
It is worth mentioning that AstraZeneca's revenue in China is still a multinational pharmaceutical company with a relatively high proportion of global revenue, and China's revenue is still an important driving factor for the company's global performance growth
.
In order to boost performance, AstraZeneca has also made a lot of efforts since 2021, such as spending huge sums of money to acquire Alexion, a rare disease drug company, establishing a rare disease business unit, merging the two business units of “breathing” and “digestion”, splitting and County business,
etc.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Recently, AstraZeneca issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons
.
At the same time, Yu Qiran, the current director of new product planning and marketing, will also serve as the head of the project management office of the general manager of oncology
.
AstraZeneca's top management changes frequently.
According to incomplete statistics, 10 executives have left in the past 10 months, and there are many positions such as general manager and vice president
.
Among them, on March 15, 2022, Zhu Tong, vice president of AstraZeneca China and head of the Cardiovascular, Renal and Metabolism Division, announced his resignation, and his term will officially end on April 9, 2022
.
On 11, 2022, He Shuzhen, head of AstraZeneca's China and county markets, resigned
.
The reason for leaving is to seek external development opportunities
.
On December 11, 2021, Yin Min, General Manager of AstraZeneca China Oncology Division, resigned.
On the same day, AstraZeneca China Vice President and Head of Retail Division Wang Dong announced his resignation
.
On November 4, 2021, Du Haochen, vice president of AstraZeneca China and head of the county business department, resigned
.
It is worth mentioning that on October 15, 2021, He Yimin, assistant vice president of AstraZeneca China Digestive and Respiratory Nebulization Business Unit (GNR), announced his resignation
.
On September 22, 2021, AstraZeneca East RGM and Chairman of the Sales Advisory Committee Zhang Anwei resigned
.
On August 4, 2021, Xu Jing, Vice President of AstraZeneca China and Head of Digital and Business Innovation Department, announced his resignation due to seeking external career development opportunities
.
In July 2021, Dong Lijun, general manager of AstraZeneca's China Digestion and Whole Product Development Business Department, announced her resignation
.
From the perspective of the industry, behind the frequent resignation of senior executives of pharmaceutical companies, it is generally related to the company's performance, structural adjustment and other factors.
.
In terms of performance, AstraZeneca's 2021 financial report released on February 10 shows that its total revenue in China is $1.
312 billion, down from $1.
362 billion in 2020, which is also AstraZeneca's China's first drop in nearly five years
.
In the fourth quarter, revenue growth in China decreased by 4% year-on-year in 2020
.
As for the reasons for the decline in performance, AstraZeneca said that the main reason is "affected by price pressures related to medical insurance negotiations and centralized procurement policies
.
" In recent years, with the normalization of centralized procurement in China and the advancement of medical insurance, multinational pharmaceutical companies have also faced corresponding challenges.
Many multinational pharmaceutical companies have resigned, business adjustments, and even inevitably ushered in a "wave of layoffs"
.
For example, after the sixth batch of insulin centralized procurement, Novo Nordisk, which participated in the selection of all products, reported that it would lay off 15%-20% of its employees nationwide; Japanese pharmaceutical companies Daiichi Sankyo's Lesong tablets, Colabitux was not selected for the fourth batch of centralized procurement.
The company plans to combine cardiovascular, anti-infective and respiratory analgesia lines and lay off related teams
.
It is worth mentioning that AstraZeneca's revenue in China is still a multinational pharmaceutical company with a relatively high proportion of global revenue, and China's revenue is still an important driving factor for the company's global performance growth
.
In order to boost performance, AstraZeneca has also made a lot of efforts since 2021, such as spending huge sums of money to acquire Alexion, a rare disease drug company, establishing a rare disease business unit, merging the two business units of “breathing” and “digestion”, splitting and County business,
etc.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
